Clinical Trial Update: Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome [Phase 2]

View source ↗

Summary

Phase 2 safety study of two doses of BMN 110 for Morquio A Syndrome has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Morquio Syndrome
• Mucopolysaccharidosis Type Iva

Drugs mentioned

• BMN 110

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Mucopolysaccharidosis IVA, Morquio A Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2016-02-01